GSK’s workers vote against ‘derisory’ pay offer

29 April 2022

Elizabeth Pfeuti

The pay offer dispute comes after GSK made significant profits in 2021 and gave its CEO a 17% pay rise.
EU regulation

GSK’s UK workers vote for industrial action over ‘derisory’ pay offer

April 29, 2022

The pay offer dispute comes after GSK made significant profits in 2021 and gave its CEO a 17% pay rise.

The UK workers of pharmaceutical giant GlaxoSmithKline (GSK) have voted for industrial action after the company offered them a 2.75% pay rise, an offer that would be a real-terms pay cut while the true rate of inflation remains at 9%.

The workers, members of the union Unite, voted 86% in favour of strike action after GSK made what the union has termed a “derisory” pay offer.

The pay offer has been especially problematic for workers in light of the £34.1 billion that the company made in profits last year from household medicines such as Sensodyne and Panadol.

In addition, GSK’s chief executive officer Emma Walmsley received a pay increase of 17% in 2021 to the tune of £8.2 million.

Sharon Graham, general secretary for Unite, said: “Never before have our members at GSK voted for strike action – their anger is a clear response to the company’s colossal corporate greed.

“GSK pocketed more than £34 billion in profits last year, yet expects its workforce to swallow a pay cut in the midst of a cost-of-living crisis. As the strength of our members’ vote shows, this is simply not acceptable – I’m backing Unite members and their demand that GSK thinks again.”

Tony Devlin, national officer at Unite, commented: “Our members at GSK have delivered a huge mandate in favour of strike action.

“Even at this late stage Unite has offered GSK a small window in which to make an improved offer and to avoid the inevitable disruption to production that will occur if strike action takes place.”

GSK is preparing for a demerger later this year when it will spin off its consumer health business into a newly independent company, called Haleon. The listing of Haleon is expected in July 2022.

Latest News

SHareholder meeting

Shareholders sue Intel amid share slump as investors increasingly turn to litigation

SHareholder meeting

Minerva Analytics Rule 14a-8 response urges SEC to preserve shareholder access through content-neutral proposal system

SHareholder meeting

SEC targets executive pay disclosures in planned broad governance reset

SHareholder meeting

Missouri sues proxy advisor over ESG voting recommendations

SHareholder meeting

Anthropic IPO raises disclosure and governance questions ahead of Nasdaq listing

SHareholder meeting

CSDDD consultation results sharpen investor focus on implementation

Featured Briefings

Minerva Briefing

2026 Europe Proxy Season Review

Minerva Briefing

Australia 2026 AGM Season Preview

Minerva Briefing

2026 United States of America Proxy Season Review

Minerva is a global provider of sustainable stewardship solutions with over 30 years of expertise. Minerva empowers investors by providing essential tools, including ESG research and data and expert insights, enabling them to navigate the intricate and ever-evolving landscape of stewardship and proxy voting, whilst ensuring their decisions are well-informed and aligned with sustainable principles.

Related Stories

SEC targets executive pay disclosures in planned broad governance reset

SEC targets executive pay disclosures in planned broad governance reset

November 17, 2026
Read More
Missouri sues proxy advisor over ESG voting recommendations

Missouri sues proxy advisor over ESG voting recommendations

November 17, 2026
Read More

Anthropic IPO raises disclosure and governance questions ahead of Nasdaq listing

November 13, 2026
Read More

Does the blue tsunami spell the end of the anti-ESG crusade?

November 5, 2026
Read More

FCA finalises ESG ratings regime, bringing providers into regulatory framework

November 5, 2026
Read More
Shein lists in Hong Kong at reduced valuation after protracted IPO journey

Shein lists in Hong Kong at reduced valuation after protracted IPO journey

September 2, 2026
Read More